https://www.selleckchem.com/pr....oducts/liproxstatin-
ipid metabolic profiles in vivo. This discrepancy between in vitro and in vivo regulation mechanisms suggests that ceramide plays a role in non-alcoholic fatty liver disease and insulin resistance. The aim of this study was to investigate whether a new generic rosuvastatin is non-inferior to a proprietary one in terms of lipid-lowering efficacy. We also evaluated its non-lipid effects including adverse events. One-hundred and fifty-eight patients with cardiovascular risks requiring pharmacological lipid-lowering therapy were scre
Like
Comment
Share
